Objectif Degenerative diseases of old age, including cardiovascular diseases, type II diabetes, and chronic respiratory conditions, have emerged as the major causes of death in EU countries. Of special concern are neurodegenerative conditions including Alzheimer’s and Parkinson’s, which have been described as the greatest unmet need facing modern medicine. Developing new therapies to slow, halt, or reverse these pathologies is regarded as a key element in addressing this global health priority. No such therapies have been successfully developed to date.A major unsolved challenge faced by drug discovery organisations is that for most degenerative conditions, there are no prognostic markers that can be used to predict whether a candidate therapy is likely to improve clinical outcome.Our solution to this problem exploits the fact that the pathogenesis and progression of all degenerative diseases is associated with oxidative stress. Oxidative stress thus makes an excellent potential prognostic biomarker, but it has been difficult to measure in vivo. Now, under the REDOX ERC Advanced Investigator Award, we have developed a portfolio of next-generation mouse models in which oxidative stress can be monitored at single-cell resolution across all organs. Moreover, the measurements can also be performed non-invasively and in real-time. We believe that these mice provides a new platform with unprecedented utility that can be used by drug-discovery organisations to accelerate, reduce the costs, and increase the predictive power of their pre-clinical pipelines for degenerative conditions. To support commercial exploitation of these models, we will:a) Show that our oxidative stress biomarkers are elevated in mouse models for two degenerative conditions, Alzheimer’s and Hutchinson-Gilford Progeria Syndrome.b) Demonstrate that the biomarker signals are reduced in mice administered therapies believed to be disease-modifying. Champ scientifique medical and health sciencesbasic medicinepharmacology and pharmacydrug discoverymedical and health sciencesbasic medicineneurologydementiaalzheimermedical and health sciencesclinical medicineendocrinologydiabetesmedical and health sciencesclinical medicinecardiologycardiovascular diseasesmedical and health sciencesbasic medicineneurologyparkinson Programme(s) H2020-EU.1.1. - EXCELLENT SCIENCE - European Research Council (ERC) Main Programme Thème(s) ERC-PoC-2016 - ERC-Proof of Concept-2016 Appel à propositions ERC-2016-PoC Voir d’autres projets de cet appel Régime de financement ERC-POC - Proof of Concept Grant Institution d’accueil UNIVERSITY OF DUNDEE Contribution nette de l'UE € 149 961,00 Adresse Nethergate DD1 4HN Dundee Royaume-Uni Voir sur la carte Région Scotland Eastern Scotland Angus and Dundee City Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 149 961,00 Bénéficiaires (1) Trier par ordre alphabétique Trier par contribution nette de l'UE Tout développer Tout réduire UNIVERSITY OF DUNDEE Royaume-Uni Contribution nette de l'UE € 149 961,00 Adresse Nethergate DD1 4HN Dundee Voir sur la carte Région Scotland Eastern Scotland Angus and Dundee City Type d’activité Higher or Secondary Education Establishments Liens Contacter l’organisation Opens in new window Site web Opens in new window Participation aux programmes de R&I de l'UE Opens in new window Réseau de collaboration HORIZON Opens in new window Coût total € 149 961,00
